PE20141316A1 - Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina - Google Patents

Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina

Info

Publication number
PE20141316A1
PE20141316A1 PE2013002710A PE2013002710A PE20141316A1 PE 20141316 A1 PE20141316 A1 PE 20141316A1 PE 2013002710 A PE2013002710 A PE 2013002710A PE 2013002710 A PE2013002710 A PE 2013002710A PE 20141316 A1 PE20141316 A1 PE 20141316A1
Authority
PE
Peru
Prior art keywords
subject
reduced
multiple sclerosis
preserve
methods
Prior art date
Application number
PE2013002710A
Other languages
English (en)
Spanish (es)
Inventor
Katherine Dawson
Gilmore O'neill
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of PE20141316A1 publication Critical patent/PE20141316A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2013002710A 2011-05-26 2012-05-25 Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina PE20141316A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
PE20141316A1 true PE20141316A1 (es) 2014-10-01

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002710A PE20141316A1 (es) 2011-05-26 2012-05-25 Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina

Country Status (19)

Country Link
US (1) US20140163100A1 (https=)
EP (1) EP2713724A4 (https=)
JP (1) JP2014515373A (https=)
KR (1) KR20140036257A (https=)
CN (1) CN103732062A (https=)
AU (1) AU2012258558A1 (https=)
BR (1) BR112013030169A2 (https=)
CA (1) CA2836480A1 (https=)
CL (1) CL2013003358A1 (https=)
CO (1) CO6811862A2 (https=)
EA (1) EA201391578A1 (https=)
EC (1) ECSP13013117A (https=)
IL (1) IL229448A0 (https=)
MX (1) MX2013013781A (https=)
PE (1) PE20141316A1 (https=)
PH (1) PH12013502443A1 (https=)
SG (1) SG195049A1 (https=)
WO (1) WO2012162669A1 (https=)
ZA (1) ZA201308681B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526586C (en) 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL2316430T3 (pl) 2004-10-08 2012-11-30 Forward Pharma As Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
KR20150080037A (ko) 2011-06-08 2015-07-08 바이오젠 엠에이 인코포레이티드 고순도 및 결정질 다이메틸 푸마레이트의 제조 방법
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2882730C (en) 2012-08-22 2019-12-31 Arbor Pharmaceuticals, Llc Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031901A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of use for monomethyl fumarate and prodrugs thereof
EP2934503B1 (en) 2012-12-21 2019-04-10 Biogen MA Inc. Deuterium substituted fumarate derivatives
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JP6564868B2 (ja) * 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
KR20200013086A (ko) 2014-12-11 2020-02-05 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
GB201907882D0 (en) 2019-06-03 2019-07-17 Cyprus Foundation For Muscular Dystrophy Res Methods
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
RU2554347C2 (ru) * 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
JP2012525385A (ja) * 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療

Also Published As

Publication number Publication date
ZA201308681B (en) 2017-11-29
BR112013030169A2 (pt) 2016-08-09
MX2013013781A (es) 2014-01-08
SG195049A1 (en) 2013-12-30
EA201391578A1 (ru) 2014-05-30
IL229448A0 (en) 2014-01-30
CN103732062A (zh) 2014-04-16
CA2836480A1 (en) 2012-11-29
US20140163100A1 (en) 2014-06-12
EP2713724A4 (en) 2015-03-11
ECSP13013117A (es) 2014-06-30
PH12013502443A1 (en) 2019-03-22
CL2013003358A1 (es) 2014-08-01
CO6811862A2 (es) 2013-12-16
WO2012162669A1 (en) 2012-11-29
EP2713724A1 (en) 2014-04-09
JP2014515373A (ja) 2014-06-30
KR20140036257A (ko) 2014-03-25
AU2012258558A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
PE20141316A1 (es) Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina
IN2014CN04748A (https=)
CY1120385T1 (el) Μεθοδος για την επεξεργασια της τεφρας, ιδιαιτερως της πτητικης τεφρας
MX2011007930A (es) Conjugados de insulina cristalina.
MY199027A (en) Method for treating or preventing ophthalmological conditions
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
CL2011000513A1 (es) Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina.
GB2510703A (en) Travel headrest
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
MX364220B (es) Metodos de tratamientos de fibrosis.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
DK201300530A (en) Vaccine relating to Pancreas disease in fish
CR20140075A (es) Métodos terapéuticos
WO2013085431A3 (en) Medical food for the dietary management of depression and anxiety and methods thereof
SG195170A1 (en) Methods of treating or preventing rheumatic disease
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
EP3449917A3 (en) Tapentadol for preventing chronification of pain
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
NZ629420A (en) Sheep nematode vaccine
NZ706329A (en) Agent for enhancing immunity containing glutathione
UA103665C2 (ru) Лечение фарингита, в том числе фарингомикоза и атрофического фарингита методом лазеротерапии

Legal Events

Date Code Title Description
FD Application declared void or lapsed